Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Apr;173(1-2):153-9.
doi: 10.1007/s00213-003-1711-8. Epub 2004 Jan 15.

Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

Jessica Werth Cook  1 , Bonnie Spring, Dennis E McChargue, Belinda Borrelli, Brian Hitsman, Raymond Niaura, Nancy J Keuthen, Jean Kristeller
Affiliations
Clinical Trial

Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

Jessica Werth Cook et al. Psychopharmacology (Berl). 2004 Apr.

Abstract

Rationale: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression.

Objectives: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking.

Methods: Adult smokers (n=175) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT) for smoking cessation. We postulated that fluoxetine would beneficially influence post-cessation changes in positive and negative affect.

Results: Mood change across treatment was analyzed using mixed linear modeling controlling for initial level of nicotine dependence, plasma fluoxetine metabolites, and change in cotinine (a nicotine metabolite) at each visit. Relative to placebo, those on 60 mg fluoxetine experienced an elevation in positive affect that increased across time [t(526)=2.50, P=0.01], and a reduction in negative affect that returned to baseline across time [t(524)=2.26, P=0.02]. There were no differences between 30 mg and placebo on changes in positive or negative affect.

Conclusions: Results indicate that 60 mg of fluoxetine improves both positive and negative mood states after quitting smoking and that diminished positive affect may be an overlooked affective response to smoking cessation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Regression function showing estimated positive affect change by condition across time, covariate adjusted for change in cotinine, fluoxetine blood levels and nicotine dependence. Distances represent real time. Participants quit smoking between visit 3 and 4, 14 days after beginning of medication phase
Fig. 2
Fig. 2
Regression function showing estimated negative affect change by condition across time, covariate adjusted for change in cotinine, fluoxetine blood levels and nicotine dependence. Distances represent real time. Participants quit smoking between visit 3 and 4, 14 days after beginning of medication phase
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Vol. 4. APA; Washington D.C.: 1994.
    1. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo be serotonin agonists: studies with microdialysis. Eur J Pharmacol. 1991;200:1–8. - PubMed
    1. Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C, Abrams DB. Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry. 1996;57:534–538. - PubMed
    1. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100:316–336. - PubMed
    1. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol. 2002;100:435–444. - PubMed

Publication types

MeSH terms